in progress

Draft Research Plan

Screening for Skin Cancer

January 07, 2021

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

This document is available for Public Comments until Feb 03, 2021 11:59 PM EST

In an effort to maintain a high level of transparency in our methods, we open our Draft Research Plan to a public comment period before we publish the final version.

Leave a Comment >>

Note: For all Key Questions and Contextual Questions, “skin cancer” refers to melanoma and keratinocyte carcinomas (basal cell carcinoma and squamous cell carcinoma).

  1. What is the effectiveness of routine skin cancer screening with visual skin examination by clinicians in reducing skin cancer morbidity and mortality or all-cause mortality?
    1. Does the effectiveness of screening vary by subgroups (e.g., age, sex, skin type, or ultraviolet [UV] exposure)?
  2. Does routine skin cancer screening lead to higher rates of detection of skin cancer at a precancerous or early stage compared to usual care (e.g., lesion-directed skin examination)?
    1. Do rates of earlier skin cancer detection vary by subgroups (e.g., age, sex, skin type, or UV exposure)?
  3. What are the harms of skin cancer screening and diagnostic followup?
    1. Do the harms of screening vary by subgroups (e.g., age, sex, skin type, or UV exposure)?
  4. What is the association between detection of skin cancer at a precancerous or early stage and morbidity and mortality due to skin cancer or all-cause mortality?

Contextual questions will not be systematically reviewed and are not shown in the Analytic Framework.

  1. What validated risk assessment tools are available for assessing skin cancer risk in primary care?
  2. What is the potential for overdiagnosis and overtreatment associated with skin cancer screening?
  3. What is the test performance of routine skin cancer screening in a primary care or dermatology setting?
  4. What are the serious harms of treatment of skin cancer?

The Proposed Research Approach identifies the study characteristics and criteria that the Evidence-based Practice Center will use to search for publications and to determine whether identified studies should be included or excluded from the Evidence Review. Criteria are overarching as well as specific to each of the Key Questions.

Proposed inclusion and exclusion criteria are generally consistent with the 2016 review. However, outcomes for Key Question 2 now are focused on stage or lesion thickness at detection of skin cancer or precancerous lesion, rather than on the diagnostic accuracy of screening by primary care clinicians compared to screening by dermatologists.

  Include Exclude
Population KQs 1–3: Asymptomatic adolescents and adults age 15 years and older with or without a family history of melanoma

KQ 4: Adolescents and adults age 15 years and older diagnosed with skin cancer

Individuals younger than age 15 years

KQs 1–3: Individuals under surveillance for skin cancer (e.g., previous skin cancer; genetic syndromes associated with increased skin cancer risk; conditions associated with an immunosuppressed state)

Settings
  • Primary care–relevant settings
  • In-person or virtual settings
  • Countries categorized as “Very High” on the 2019 Human Development Index (as defined by the United Nations Programme)
KQs 1, 2: Conducted exclusively in specialty care settings (e.g., dermatology/plastic surgery)
Screening tests Total or partial visual skin examination conducted by a clinician with or without tools to aid examination (including but not limited to, dermatoscopy, whole body photography)
  • Lesion-directed diagnostic skin examination (e.g., in response to patient concern)
  • Skin self-examination or behavioral counseling by clinician for self-examination*
Comparison KQs 1, 2: No visual skin examination

KQ 2: Usual care (e.g., lesion-directed examination)

KQ 4: Stage at detection (precancerous lesions or skin cancer)

 
Outcomes KQs 1, 4: Morbidity associated with skin cancer, including quality of life; skin cancer mortality; all-cause mortality

KQ 2: Stage or lesion thickness at detection of skin cancer or precancerous lesion

KQ 3: Any persistent harm (beyond 30 days) from screening, biopsy, or excision; including psychosocial harms and procedure-related adverse events

KQs 1, 2, 4:
  • Non-skin location
  • Risk reduction behaviors (e.g., skin self-examination, sun protective behaviors) or measures of doctor-patient relationship quality
  • Outcomes not stratified by skin cancer type (melanoma vs. non-melanoma skin cancers)
Study design All KQs: Fair- and good-quality studies

KQs 1, 2, 4: Randomized, controlled trials; controlled clinical trials; observational or nonrandomized studies with a contemporaneous control

KQ 3: Randomized, controlled trials; controlled clinical trials; large screening registry or database; observational studies; cohort studies; and systematically selected case series
All KQs: Poor-quality studies

KQs 1, 2: Decision analyses

KQ 3: Case studies

* Covered in 2018 evidence review on behavioral counseling for skin cancer prevention.1

1. Henrikson NB, Morrison CC, Blasi PR, et al. Behavioral counseling for skin cancer prevention: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(11):1143-1157.